Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0225
REVIEW
|
| Predictive molecular tools to personalized gastric cancer targeted therapy.
|
Edwin Sandanaraj, PhD and Joanna Holbrook, PhD.
|
Affiliation: (ES) and (JH) both from Singapore Institute of Clinical Sciences (SICS), Agency for Science and Technology (A*STAR), Brenner Centre for Molecular Medicine, 30 Medical Drive, Singapore, 117609.
E-mail: joanna_holbrook@sics.a-star.edu.sg
|
Summary
Trastuzumab has been the first targeted agent approved by the FDA for the first line treatment of ERBB2-positive advanced gastric cancer patients. This anti-HER2 drug provides evidence for significant overall survival benefit. However, the ERRB2 signalling pathways activation has been seen observed in only about 7-25% of gastric cancer patients with no trastuzumab antitumor activity for the remaining ERBB2-negative proportion. Large-scale clinical trials such as the TOGA and AVAGAST have explored prognostic biomarker identification to enhance clinical outcome. However, the high level of genetic and molecular heterogeneity within gastric tumours, across time, across patients and across geographical regions remains a substantial challenge. Characterization of activated signalling pathways that is crucial for both biomarkers development and drugs selection, in individual patients still remains a grand challenge. In this review, we evaluate the profiling of oncogenic pathways that is likely to confer sensitivity to available targeted therapies. Advances and challenges are discussed.
(Citation: Gastric & Breast Cancer 2012; 11(3) 166-179).
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 10 July 2012 |
|
